Literature DB >> 2982990

Serum factor requirement for reactive oxygen intermediate release by rabbit alveolar macrophages.

G F Gerberick, J B Willoughby, W F Willoughby.   

Abstract

Alveolar macrophages (AM) from pathogen-free rabbits were unable to release reactive oxygen intermediates (ROI) unless they were conditioned in serum for 24-48 h before triggering with membrane-active agents. The degree of serum conditioning of AM depended upon the concentration of serum used; optimal ROI release was obtained at or above 7.5% fetal bovine serum (FBS). FBS, autologous rabbit serum, pooled rabbit serum, and pooled human serum were each capable of conditioning AM for release of ROI. Serum conditioning of AM requires synthesis of new protein(s); and the enzyme required for ROI production, NADPH oxidase, was only detectable in serum-conditioned cells. Moreover, serum-conditioned cells lost their ability to release ROI after transfer to serum-free medium, while cells maintained in serum-free medium acquired the capacity to release ROI after their transfer to serum-containing medium, demonstrating the reversibility of the phenomenon. Initial purification data indicate that conditioning is mediated by a discrete serum constituent, which precipitates 40-80% saturated ammonium sulfate, does not bind to Cibacron Blue columns, and has a molecular weight of 30,000 to 50,000, as determined by molecular exclusion chromatography. Unlike gamma interferon, which also enhances ROI release by macrophages, our serum-conditioning factor is not acid labile, retaining 67% of its activity after 120 min incubation at pH 2.0. Moreover, it does not appear to be a contaminating endotoxin, since LPS neither conditioned AM for ROI production, nor triggered ROI production by serum-conditioned AM. We propose that such a conditioning requirement may normally protect the lung against ROI-mediated tissue injury. However, during a pulmonary inflammatory reaction initiated by other mediator systems, the resulting transudation of plasma proteins into the alveolar spaces may condition AM in situ for ROI production.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982990      PMCID: PMC2187563          DOI: 10.1084/jem.161.2.392

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  Oxygen metabolism in the alveolar macrophage: friend and foe?

Authors:  J Bernard; J B Gee; A S Khandwala
Journal:  J Reticuloendothel Soc       Date:  1976-04

2.  Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid.

Authors:  H A Chapman; J B Hibbs
Journal:  Science       Date:  1977-07-15       Impact factor: 47.728

3.  Increased superoxide anion production by immunologically activated and chemically elicited macrophages.

Authors:  R B Johnston; C A Godzik; Z A Cohn
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

4.  The effect of phorbol myristate acetate on the metabolism and ultrastructure of human alveolar macrophages.

Authors:  J R Hoidal; J E Repine; G D Beall; F L Rasp; J G White
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

5.  Reactive forms of oxygen and chemiluminescence in phagocytizing rabbit alveolar macrophages.

Authors:  P R Miles; V Castranova; P Lee
Journal:  Am J Physiol       Date:  1978-09

6.  Effects of fatty acids on superoxide radical generation in leukocytes.

Authors:  K Kakinuma; S Minakami
Journal:  Biochim Biophys Acta       Date:  1978-01-03

7.  Characterization of the metabolic responses of the human pulmonary alveolar macrophage.

Authors:  G Papermaster-Bender; M E Whitcomb; A L Sagone
Journal:  J Reticuloendothel Soc       Date:  1980-08

8.  Stimulation of the hexose monophosphate shunt independent of hydrogen peroxide and superoxide production in rabbit alveolar macrophages during phagocytosis.

Authors:  M F Tsan
Journal:  Blood       Date:  1977-11       Impact factor: 22.113

9.  Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering.

Authors:  C F Nathan; R K Root
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

10.  Chemiluminescence of phagocytic cells caused by N-formylmethionyl peptides.

Authors:  G E Hatch; D E Gardner; D B Menzel
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Cryopreserved normal macrophages as a control for assays of macrophage function.

Authors:  L S Lamb; J B Willoughby; W F Willoughby
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-02       Impact factor: 2.416

Review 2.  Polyclonal activators in pulmonary immune disease.

Authors:  W F Willoughby; J B Willoughby; G F Gerberick
Journal:  Clin Rev Allergy       Date:  1985-05

3.  Endogeneous interferon alpha/beta produced by murine Kupffer cells augments liver-associated natural killing activity.

Authors:  M Werner-Wasik; W von Muenchhausen; J P Nolan; S A Cohen
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  A continuous alveolar macrophage cell line: comparisons with freshly derived alveolar macrophages.

Authors:  R J Helmke; V F German; J A Mangos
Journal:  In Vitro Cell Dev Biol       Date:  1989-01

5.  The effect of products from bronchoalveolar-derived neutrophils on oxidant production and phagocytic activity of alveolar macrophages.

Authors:  K Donaldson; J Slight; R E Bolton
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

6.  Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases.

Authors:  B Wallaert; F Bart; C Aerts; A Ouaissi; P Y Hatron; A B Tonnel; C Voisin
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

7.  Oxygen-independent killing by alveolar macrophages.

Authors:  J R Catterall; S D Sharma; J S Remington
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

8.  Enhancement of polymorphonuclear leukocyte-mediated tumor cytotoxicity by serum factor(s).

Authors:  A Araki; T Inoue; S Kimura; S Fukase; F Sendo
Journal:  Jpn J Cancer Res       Date:  1990-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.